PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges

被引:201
作者
Khan, Mohammad A. [1 ]
Jain, Vineet K. [3 ]
Rizwanullah, Md. [4 ]
Ahmad, Javed [2 ]
Jain, Keerti [3 ]
机构
[1] Jamia Hamdard, Sch Pharmaceut Educ & Res, Dept Pharmacol, New Delhi 110062, India
[2] Najran Univ, Coll Pharm, Dept Pharmaceut, Najran, Saudi Arabia
[3] DPSRU, New Delhi 110017, India
[4] Jamia Hamdard, Sch Pharmaceut Educ & Res, Dept Pharmaceut, New Delhi 110062, India
关键词
THERAPEUTIC TARGETS; EXPRESSION; DELIVERY; CELLS; PROGRESSION; METASTASIS; THERAPIES; TRIALS; PD-L1;
D O I
10.1016/j.drudis.2019.09.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Triple-negative breast cancer (TNBC) is a highly malignant subtype of breast cancer associated with poor prognosis. Although conventional chemotherapy regimens have shown some effectiveness in early TNBC cases, the outcome in advanced stages is poor. The PI3K/AKT/mTOR pathway is one of the important and active pathways involved in chemoresistance and survival of TNBC. This pathway is speculated to play an important part in malignant transformation and has been considered as a potential molecular target for the design of therapeutic agents to treat TNBC. This review discusses the potentials and drug discovery perspectives of PI3K/AKT/mTOR as a therapeutic target for effective management of TNBC with anticipated challenges.
引用
收藏
页码:2181 / 2191
页数:11
相关论文
共 63 条
[1]   3D Printing in Personalized Drug Delivery [J].
Afsana ;
Jain, Vineet ;
Haider, Nafis ;
Jain, Keerti .
CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (42) :5062-5071
[2]  
Agoulnik IU, 2011, ONCOTARGET, V2, P321
[3]   Dendrosomal nanocurcumin and exogenous p53 can act synergistically to elicit anticancer effects on breast cancer cells [J].
Baghi, Narges ;
Bakhshinejad, Babak ;
Keshavarz, Reihaneh ;
Babashah, Sadegh ;
Sadeghizadeh, Majid .
GENE, 2018, 670 :55-62
[4]   The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress [J].
Bahrami, Afsane ;
Khazaei, Majid ;
Shahidsales, Soodabeh ;
Hassanian, Seyed Mahdi ;
Hasanzadeh, Malihe ;
Maftouh, Mina ;
Ferns, Gordon A. ;
Avan, Amir .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2018, 119 (01) :213-222
[5]   Dietary restriction: could it be considered as speed bump on tumor progression road? [J].
Cangemi, Antonina ;
Fanale, Daniele ;
Rinaldi, Gaetana ;
Bazan, Viviana ;
Galvano, Antonio ;
Perez, Alessandro ;
Barraco, Nadia ;
Massihnia, Daniela ;
Castiglia, Marta ;
Vieni, Salvatore ;
Bronte, Giuseppe ;
Mirisola, Mario ;
Russo, Antonio .
TUMOR BIOLOGY, 2016, 37 (06) :7109-7118
[6]   Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 [J].
Coates, A. S. ;
Winer, E. P. ;
Goldhirsch, A. ;
Gelber, R. D. ;
Gnant, M. ;
Piccart-Gebhart, M. ;
Thuerlimann, B. ;
Senn, H. -J. .
ANNALS OF ONCOLOGY, 2015, 26 (08) :1533-1546
[7]   Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review [J].
Costa, Ricardo L. B. ;
Han, Hyo Sook ;
Gradishar, William J. .
BREAST CANCER RESEARCH AND TREATMENT, 2018, 169 (03) :397-406
[8]   Emerging targeted therapies in triple-negative breast cancer [J].
Crown, J. ;
O'Shaughnessy, J. ;
Gullo, G. .
ANNALS OF ONCOLOGY, 2012, 23 :56-65
[9]   Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling [J].
Cuenca-Lopez, Maria D. ;
Montero, Juan C. ;
Morales, Jorge C. ;
Prat, Aleix ;
Pandiella, Atanasio ;
Ocana, Alberto .
BMC CANCER, 2014, 14
[10]   Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells [J].
dos Reis, Larissa Menezes ;
Adamoski, Douglas ;
Oliveira Souza, Rodolpho Ornitz ;
Rodrigues Ascencao, Carolline Fernanda ;
Sousa de Oliveira, Krishina Ratna ;
Correa-da-Silva, Felipe ;
de Sa Patroni, Fabio Malta ;
Dias, Marilia Meira ;
Consonni, Silvio Roberto ;
Mendes de Moraes-Vieira, Pedro Manoel ;
Silber, Ariel Mariano ;
Gomes Dias, Sandra Martha .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2019, 294 (24) :9342-9357